跳至主要内容
临床试验/IRCT2012091510842N1
IRCT2012091510842N1已完成4 期

Comparison of efficacy and safety of oral itraconazole with placebo in the primary treatment and maintenance therapy of moderate to severe seborrheic dermatitis.

Tehran University of Medical Sciences0 个研究点目标入组 68 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
68

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • Moderate to severe seborrheic dermatitis that will be diagnosed clinically by a dermatologist +/- Recurrent seborrheic dermatitis +/- Seborrheic dermatitis resistant to Topical therapy; Age =18; Patients willing to take part in the study and expected to be available for the duration of study and comply with study visits. Exclusion criteria: Seborrheic Dermatitis(SD) associated with any other papulosquamous dermatoses like psoriasis, rosacea, lupus erythematous, lichen planus, tinea, and eczema; Significant renal or liver disease; AIDS; Parkinson Disease; Allergy to azoles; Drug use interfering with itraconazole; Very severe dermatitis defined by erythrodermia or extensive flexural involvement; Use of topical therapy (except moisturizers) and systemic therapy in last 2 week and 1 month, respectively; Pregnancy and lactation.

排除标准

  • 未提供

研究者

相似试验